Barclays analyst Matt Miksic lowered the firm’s price target on Insulet to $257 from $329 and keeps an Equal Weight rating on the shares. The company’s sales and margin upside supports the increase in 2023 guidance, but concerns over the long-term impact of GLP-1s continues to put pressure on Insulet and the other diabetes names, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PODD: